Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Q1 Revenues Flat on Currency Effects

NEW YORK (GenomeWeb) – Bio-Rad Laboratories reported after the close of the market Thursday that its first quarter revenues were essentially flat year over year but increased 4 percent on a currency-neutral basis.

For the three months ended March 31, the Hercules, California-based company recorded $471.2 million in revenues compared to $472.8 million in Q1 2015. On a conference call to recap the company's earnings, Bio-Rad Vice President and CFO Christine Tsingos said that this decline reflects continued strong currency headwinds, which represented a negative impact on sales of nearly $20 million.

Life Science segment sales increased 6 percent year over year to $165.9 million. On a currency-neutral basis, Life Science sales increased 10 percent compared to the year-ago period. Growth in the segment was driven by sales of the firm's Droplet Digital PCR and process media products.

Meantime, Q1 Clinical Diagnostics sales dropped 4 percent to $301.7 million, but grew 1 percent on a currency-neutral basis. These results reflected modest growth across most product lines, most notable clinical immunology, quality controls, and diabetes products, Bio-Rad said.

During the quarter Bio-Rad received CE IVD marking for its QX200 Droplet Digital PCR system, which will allow clinical end users in Europe to use the platform for detection and quantification of nucleic acids to aid clinical decision making.

Also during the quarter, Bio-Rad and Illumina announced an exclusive partnership to develop a next-generation sequencing workflow for single-cell analysis that will leverage a modified version of the QX200 platform.

Bio-Rad also disclosed today that in Q1 it acquired a high-performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad did not disclose financial details of the acquisition, but said that it expects to launch the instrument later this year.

Bio-Rad's net income in Q1 was $12.3 million, or $.42 per share, compared to $17.8 million, or $.61 per share, in the same quarter last year.

The company said that the decrease was due to lower gross margins during the quarter as well as an increase in R&D expenses, which rose 3 percent to $48.6 million from $47.2 million in the year-ago period. SG&A expenses, meanwhile, grew a half a percent to $189.7 million from $188.6 million.

Bio-Rad finished the quarter with $403.6 million in cash and cash equivalents, and $349.3 million in short-term investments.

During the earnings call, Tsingos reiterated the company's previously announced guidance of currency-neutral sales growth of 2.5 percent to 3 percent for 2016.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.